On Jun. 14 2022, Oragenics announced the publication of an article co-authored by Oragenics and collaborators at Inspirevax and the National Research Council of Canada Human Health Therapeutics Research Centre in Scientific Reports, a Nature journal.

The publication, available and titled ‘Intranasal Immunization with a Proteosome-Adjuvanted SARS-CoV2 Spike Protein-Based Vaccine is Immunogenic and Efficacious in Mice & Hamsters,’ concluded that Oragenics’ intranasal vaccine candidate, NT-CoV2-1, warranted further development as a novel SARS-CoV-2 vaccine.